Decera Clinical Education Oncology Podcast
Decera Clinical Education
0
A clinical education podcast covering new data and best practices in oncology, spanning a wide range of solid tumors and hematologic malignancies. Episodes are produced by Decera Clinical Education and offer practical clinical insights and treatment strategies for clinicians caring for patients with cancer. Selected episodes also provide CME/CE credit for listeners. The show is aimed at oncologists, hematologists, and other healthcare professionals seeking concise updates on emerging research and its application to practice.
Episodes
-
H3 K27M–Mutated Diffuse Midline Glioma: Bridging Molecular Pathology and Clinical Care 13.11.2026 40mIn this podcast, experts discuss the evolving molecular classification, diagnosis, and management of H3 K2–-altered diffuse midline glioma (DMG), emphasizing the clinical implications of histone mutations, epigenetic dysregulation, and tumor location. The discussion explores the limitations of neuroimaging, challenges associated with obtaining tissue from anatomically sensitive regions, and the importance of integrating histopathology with molecular testing to distinguish DMG from other gliomas and diagnostic mimics. Experts also examine emerging diagnostic approaches, including cerebrospinal... -
Hematologist On Call: Relapsed/Refractory Mantle Cell Lymphoma Post cBTKi 05.11.2026 26mIn this podcast episode, experts discuss the evolving treatment landscape of R/R mantle cell lymphoma as the use of covalent BTK inhibitors further expands into the first-line setting. The discussion highlights the similarities and differences between small molecules pirtobrutinib and sonrotoclax including patient selection, step-up dosing requirements, TLS monitoring, efficacy post covalent BTKi, sequencing, and the feasibility of implementing treatment in community practices. They also examine the dosing, efficacy, and safety of CAR T-cell therapy and bispecific antibodies, establishing thei... -
Rethinking MZL: From Established Options to T-Cell–Directed Therapies 04.11.2026 29mThis podcast explores the evolving treatment landscape for marginal zone lymphoma (MZL), focusing on individualized treatment selection, emerging cellular therapies, and novel T-cell–engaging approaches for relapsed/refractory disease. Examine evidence supporting current treatment options, including BTK inhibitors and CAR T-cell therapy, as well as emerging clinical data on CD20 x CD3 bispecific antibodies such as odronextamab and mosunetuzumab. The discussion also addresses clinical trial referral, patient eligibility, and practical strategies for monitoring and managing treatment-related tox... -
TROP2-Directed ADCs in NSCLC: Current Evidence, Emerging Therapies, and Future Treatment Strategies 29.10.2026 28mIn this podcast, experts discuss the evolving role of TROP2-directed antibody–drug conjugates (ADCs) in NSCLC, highlighting current clinical applications, emerging efficacy and safety data, and future treatment strategies. The discussion reviews evidence supporting the use of datopotamab deruxtecan (Dato-DXd) in previously treated EGFR-mutated NSCLC and considerations for treatment selection and sequencing. Emerging data for investigational TROP2 ADCs, including sacituzumab tirumotecan, and findings from ongoing trials evaluating ADC combinations with immunotherapy, chemotherapy, and EGFR-targ... -
Experts Discuss Key Topics in Treatment for Newly Diagnosed Multiple Myeloma 19.10.2026 24mListen to expert faculty discuss the evolving role of quadruplet therapy in newly diagnosed multiple myeloma, with an emphasis on treatment selection across transplant-eligible and transplant-ineligible populations, the incorporation of proteasome inhibitors, and the tailoring of treatment intensity. The experts also examine unresolved questions regarding the optimal use of bortezomib, the role of autologous stem cell transplantation in the quadruplet era, and the use of MRD status to inform treatment decisions. Maintenance strategies with lenalidomide alone or in combination with anti-CD38 th... -
PARP Inhibitors in Metastatic Prostate Cancer: Biomarker Testing, Treatment Strategies, and Toxicity Management 09.10.2026 27mIn this podcast, experts discuss the evolving role of PARP inhibitors in metastatic prostate cancer, with a focus on the biologic rationale for PARP inhibition in tumors with HRR alterations, the importance of germline and somatic genomic testing, and the clinical evidence supporting PARP inhibitor monotherapy and combinations with ARPI. The discussion highlights data from trials including AMPLITUDE and TALAPRO-3, considers how specific HRR alterations may influence treatment selection across metastatic disease settings, and reviews practical strategies for monitoring and managing adverse even... -
Experts Discuss Sequencing of Therapies for Relapsed/Refractory Multiple Myeloma 30.09.2026 28mIn relapsed/refractory multiple myeloma, prior therapy can affect subsequent treatment efficacy, highlighting the importance of thoughtful sequencing and consideration of alternative targets. Listen to Jesus G. Berdeja, MD, and Ajai Chari, MD, as they discuss sequencing of antibody–drug conjugates, bispecific antibodies, CAR T-cell therapy, and other novel treatment modalities for patients with relapsed/refractory multiple myeloma. -
ASCO 2026 Updates in Metastatic Breast Cancer 22.09.2026 18mIn this podcast, experts review practice-informing data presented at the ASCO 2026 annual conference that may reshape treatment decisions in metastatic breast cancer. The discussion examines ctDNA-guided treatment adaptation for emergent ESR1 mutations in HR-positive/HER2-negative disease, emerging endocrine-based precision strategies targeting ER and PI3K/AKT signaling, and first-line TROP2-directed antibody-drug conjugates in metastatic triple-negative breast cancer. The experts place the SERENA-6, ELEVATE, PIKALO-1, ASCENT-04, ASCENT-03, and TROPION-Breast02 findings in clinical context and... -
Evolving Role of B7-H3–Directed ADCs in the Extensive-Stage Small-Cell Lung Cancer Treatment Landscape 10.09.2026 35mThe care of patients with extensive-stage (ES) small-cell lung cancer (SCLC) continues to evolve with the continuous release of new clinical evidence. Listen to this podcast with 2 experts discussing current gaps and clinical needs for patients with relapsed ES-SCLC, the scientific rationale for targeting B7-H3 and other tumor-associated antigens in SCLC, the expanding role of antibody–drug conjugates (ADCs) and T-cell engagers in ES-SCLC including recent efficacy and safety data for B7-H3–directed ADCs such as ifinatamab deruxtecan (I-DXd) in ES-SCLC and the strengths and limitations of the a... -
Targeting CDH6 in Platinum-Resistant Ovarian Cancer: Emerging ADCs, Biomarkers, and Sequencing 04.09.2026 29mIn this podcast episode, experts discuss the scientific rationale and emerging clinical evidence for targeting CDH6 in platinum-resistant ovarian cancer, with a focus on CDH6-directed antibody–drug conjugates (ADCs) such as raludotatug deruxtecan and other investigational agents. The discussion examines CDH6 expression in ovarian tumors, the current limitations of biomarker testing and patient selection, and how ADC characteristics, including target expression, payload, linker properties, and drug-to-antibody ratio, may influence efficacy. Experts also review early clinical activity and key to... -
ASCO 2026 Updates in Early Hormone Receptor–Positive Breast Cancer 04.09.2026 9mIn this podcast, experts review 2 of the most important studies presented at the ASCO 2026 annual conference that inform treatment decisions for patients with early-stage hormone receptor–positive/HER2-negative breast cancer. The discussion focuses on the phase III OPTIMA trial, which evaluated Prosigna PAM50-guided chemotherapy selection and the potential for chemotherapy de-escalation in selected patients, with stimulating insights on the role of ovarian function suppression with endocrine therapy in premenopausal women. Their discussion also examines the NATALEE PAM50 biomarker analysis, wh... -
CELMoDs on the Horizon: A New Chapter in Lymphoma Care 24.08.2026 22mIn this podcast, 2 experts explore the evolving role of CELMoD-based strategies in lymphoma, with a focus on the biologic mechanisms and emerging clinical evidence for golcadomide in diffuse large B-cell lymphoma and follicular lymphoma. Listeners will hear how CELMoDs differ from established immunomodulatory and immune-based therapies, review evidence from ongoing and early-phase studies of golcadomide as monotherapy and in combination regimens, and consider practice-relevant issues including efficacy, toxicity, treatment sequencing, combination strategies, and the experts’ thoughts on how em... -
Experts Discuss Health Disparities and Equitable Care Strategies in Multiple Myeloma 20.08.2026 13mListen to Jesus G. Berdeja, MD, and Ajai Chari, MD, as they discuss health disparities and equitable care strategies in multiple myeloma, including treatment for underserved populations and keys for everyday practice. -
Experts Discuss CELMoD Agents for Multiple Myeloma 20.08.2026 26mListen to expert faculty as they discuss the use of CELMoD agents to manage multiple myeloma, including a recent approval, mechanism of action and differentiation from IMiDs, current data, and potential treatment settings. -
Optimizing Oral Targeted Therapies for HR+/HER2- Breast Cancer 14.08.2026 32mOral targeted therapies are increasingly used across early-stage and metastatic HR-positive/HER2-negative breast cancer, but optimal use can be complicated by disease setting, biomarker results, prior therapy, tolerability concerns, and adherence needs. In this podcast, expert faculty discuss current evidence and practical strategies for selecting and sequencing oral targeted therapies, applying biomarker-informed decision-making, monitoring and managing adverse events, and using pharmacist-led approaches to support adherence and long-term treatment persistence. -
TGCT Today: Understanding Diagnosis, Treatment, and Long-term Care 13.08.2026 36mTenosynovial giant cell tumor (TGCT) can present significant diagnostic and management challenges, particularly in patients with diffuse disease where symptoms, functional limitations, and risk of recurrence may substantially affect quality of life. In this podcast, expert faculty discuss the evolving TGCT treatment landscape, including the biologic rationale for targeting the CSF1/CSF1R pathway, the role of imaging and multidisciplinary care, patient-centered treatment goals, and practical considerations for integrating surgery and systemic therapies into individualized management strategies. -
Optimizing Anti-CD38–Based Treatment for Smoldering and Newly Diagnosed Multiple Myeloma: Pharmacist Perspectives 12.08.2026 28mThis podcast examines evidence guiding the use of anti-CD38–based therapy in smoldering and newly diagnosed multiple myeloma, including risk stratification, transplant eligibility, frailty, and measurable residual disease assessments. Pharmacists review findings from pivotal trials of daratumumab- and isatuximab-containing regimens, discuss triplet and quadruplet treatment strategies for transplant-eligible and transplant-ineligible patients, and consider the evolving roles of transplantation, maintenance therapy, and response-adapted care. The discussion also addresses pharmacist-led supporti... -
New and Emerging Targeted Therapies for Patients With DLBCL 07.08.2026 38mThe management of patients with DLBCL is rapidly changing with several targeted agents across different drug classes on the near horizon. Experts discuss the potential utility of surovatamig, a novel bispecific antibody targeting CD19 and CD3 in overcoming resistance to CD20-targeted therapies, and the potential roles of golcadomide, a first-in-class oral CELMoD, and tafasitamab plus lenalidomide and R-CHOP in untreated DLBCL. They also discuss ongoing trials of other bispecific antibodies and acalabrutinib, a BTK inhibitor, in DLBCL. Listen to this podcast with 2 experts from Europe and the U... -
Changing the Paradigm in HER2-Positive Early Breast Cancer 07.08.2026 25mThe DESTINY-Breast11 and DESTINY-Breast05 trials of trastuzumab deruxtecan are changing the paradigm for HER2-positive early breast cancer, but the broad new indications leave questions about sequencing and patient choice. Listen to Shanu Modi, MD, and Sara A. Hurvitz, MD, FACP, discuss how they are incorporating these changes into clinical practice in the neoadjuvant, adjuvant, and possibly metastatic settings. -
Recent Advances, Future Directions, and Ideas on Integrating CELMoDs Into The Care Of Patients With Myeloma 03.08.2026 17mListen to this podcast to hear Sagar Lonial, MD, FACP, FASCO, and Mohamad Mohty, MD, PhD, discuss recent advances, future directions, and the integration of novel protein degradation modulator-based therapy into myeloma care, including what clinicians may expect when incorporating these therapies into practice.
Popular in
The podcast also appears in the podcast charts of these countries.